|
Göran Forsberg, Chief Business Officer at Active Biotech joins Isogenica as non-executive Director
|
|
Read more... |
Isogenica Ltd today announced the opening of a new automation facility at their current location, Chesterford Research Park.
|
|
Read more... |
Isogenica Ltd today announced a collaborative joint venture with Biolauncher Ltd (Cambridge, UK) and Cresset Biomolecular Discovery Ltd (Welwyn Garden City, UK) to develop an innovative end-to-end therapeutic discovery platform.
|
|
Read more... |
Isogenica expands business development and customer support operations into North America
Californian office established to support existing and prospective customers
|
|
Read more... |
Isogenica Ltd Announces Collaboration with
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
|
Read more... |
Isogenica successfully hit milestones in relation to collaboration announced in 2010
Release Date: February 25 2011 Isogenica Ltd (Cambridge, UK) and Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian drug discovery company, today announced the successful outcome of their proof-of-concept project to demonstrate the compatibility of Isogenica’s proprietary CIS display technology with Phylogica’s Phylomer drug discovery platform.
|
|
Read more... |
Release date: 2 November 2010 , Cambridge UK
Isogenica announces new collaboration with Professor Sir Tom Blundell of the University of Cambridge
Isogenica and the University of Cambridge to apply leading edge molecular modelling to optimise Isogenica’s novel peptide scaffold libraries
Isogenica Ltd today announced that it has entered into a collaborative agreement with Professor Sir Tom Blundell of the University of Cambridge.
|
|
Read more... |
Release date: 4 October 2010
Isogenica and NovaBiotics to fast-track discovery of new applications for NovaBiotics’ anti-infective peptide technology platform
Isogenica Ltd, today announced that it has entered into a collaboration agreement with NovaBiotics, a leading clinical-stage biotechnology company to fast-track the development of Novabiotic’s anti-infective peptide technology platform.
As part of the agreement, NovaBiotics will work with Isogenica on two research projects, one concerning peptide selection and the other concerning peptide maturation with the aim of expanding Novabiotic’s product portfolio.
|
|
Read more... |
Release date: 15th February, 2010
Isogenica Ltd today announced that it has entered into an agreement with UK Ministry of Defence agency, the Defence Science and Technology Laboratory (Dstl). The agreement concerns the development of antimicrobial peptide drugs and follows a successful collaboration to identify highly effective antimicrobial peptides which are active against a broad spectrum of bacteria.
|
|
Read more... |
Perth and London: January 18, 2010
Phylogica and Isogenica today announce that they have entered into an agreement to use Isogenica’s CIS display technology to optimize the performance of three of Phylogica’s lead compounds targetingCD40 ligand (CD40L), a key protein involved in many inflammatory diseases.
|
|
Read more... |
Cambridge UK, 18th February 2009
Isogenica Ltd, developer of innovative molecular evolution technologies, is re-locating its research facility to Chesterford Research Park, taking suites 5 and 6 plus additional laboratory space at the Mansion.
|
|
Read more... |
Cambridge UK, October 2009
Isogenica Ltd, developer of innovative molecular evolution technologies, has appointed Dr Kevin Matthews as CEO.
|
|
Read more... |
Download our latest brochure and articles in PDF format (not to be reproduced)
|
